Cargando…

Determining the Minimal Important Change of Everyday Functioning in Dementia: Pursuing Clinical Meaningfulness

BACKGROUND AND OBJECTIVES: Decline in everyday functioning is a key clinical change in Alzheimer disease and related disorders (ADRD). An important challenge remains the determination of what constitutes a clinically meaningful change in everyday functioning. We aimed to investigate this by establis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubbelman, Mark A., Verrijp, Merike, Terwee, Caroline B., Jutten, Roos J., Postema, Merel C., Barkhof, Frederik, Berckel, Bart N.M., Gillissen, Freek, Teeuwen, Vivianne, Teunissen, Charlotte, van de Flier, Wiesje M., Scheltens, Philip, Sikkes, Sietske A.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502738/ https://www.ncbi.nlm.nih.gov/pubmed/35641309 http://dx.doi.org/10.1212/WNL.0000000000200781

Ejemplares similares

Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report
por: Verrijp, Merike, et al.
Publicado: (2022)

Giving meaning to the scores of the Amsterdam instrumental activities of daily living questionnaire: a qualitative study
por: Dubbelman, Mark A., et al.
Publicado: (2022)

Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
por: Jutten, Roos J., et al.
Publicado: (2021)

Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum
por: Dubbelman, Mark A., et al.
Publicado: (2020)

The Cognitive Online Self‐Test Amsterdam (COST‐A): Establishing norm scores in a community‐dwelling population
por: Visser, Leonie N.C., et al.
Publicado: (2021)

Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease
por: Villeneuve, Sarah-Christine, et al.
Publicado: (2019)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Cross-cultural adaptation and validation of the Amsterdam Instrumental Activities of Daily Living questionnaire short version German for Switzerland
por: Bruderer-Hofstetter, Marina, et al.
Publicado: (2020)

The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries
por: Dubbelman, Mark A., et al.
Publicado: (2020)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Experiences of and recommendations on clinical trial design in Alzheimer’s disease from the participant’s point of view: a mixed-methods study in two clinical trial centers in the Netherlands
por: Ottenhoff, Lois, et al.
Publicado: (2023)

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire
por: Jutten, Roos J., et al.
Publicado: (2017)

Cerebral perfusion in the predementia stages of Alzheimer’s disease
por: Binnewijzend, Maja A. A., et al.
Publicado: (2015)

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results
por: Slot, Rosalinde E. R., et al.
Publicado: (2018)

Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults
por: ten Kate, Mara, et al.
Publicado: (2018)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Enhancing ‘meaningfulness’ of functional assessments: UK adaptation of the Amsterdam IADL questionnaire
por: Stringer, Gemma, et al.
Publicado: (2021)

Dutch Brain Research Registry for study participant recruitment: Design and first results
por: Zwan, Marissa D., et al.
Publicado: (2021)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study
por: Jutten, Roos J., et al.
Publicado: (2017)

CONTEMPLATING TEMPORAL LANDMARKS, SENSING TIME, AND PURSUING A MEANINGFUL LIFE IN ADULTHOOD
por: Kim, DaEun, et al.
Publicado: (2022)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
por: Ebenau, Jarith L., et al.
Publicado: (2020)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease
por: Dorobantu, Maria, et al.
Publicado: (2017)

Steeper memory decline after COVID-19 lockdown measures
por: Bakker, Els D., et al.
Publicado: (2023)

The natural history of primary progressive aphasia: beyond aphasia
por: Ulugut, Hulya, et al.
Publicado: (2021)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score
por: Ebenau, Jarith L., et al.
Publicado: (2021)

Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2018)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Web-Based Multidomain Lifestyle Programs for Brain Health: Comprehensive Overview and Meta-Analysis
por: Wesselman, Linda MP, et al.
Publicado: (2019)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project
por: Verhaar, Barbara J.H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uj7vsovsjmj7s35o0o3kl7uv8u